Immunogenicity and Safety of a Single Dose of mRNA SARS-CoV-2 Vaccine in Chinese Adults With Hybrid Immunity

This clinical research evaluates the immunogenicity and safety of a single dose of an mRNA vaccine against the SARS-CoV-2 virus. The target group in this study consisted of Chinese adult participants with hybrid immunity. The biological intervention utilized in the project is a vaccine designated as SYS6006. The targeted medical conditions evaluated in the study were COVID-19 and SARS-CoV-2 infection. The official sponsor and organizer of this clinical project is the Jiangsu Province Centers for Disease Control and Prevention. According to the available official records, this clinical research has already been completed.